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Abstract
Gaucher disease is a progressive lysosomal storage disorder caused by the deficiency of glucocerebrosidase leading to the
dysfunction in multiple organ systems. Intravenous enzyme replacement is the accepted standard of treatment. In the
current report, we evaluate the safety and pharmacokinetics of a novel human recombinant glucocerebrosidase enzyme
expressed in transformed plant cells (prGCD), administered to primates and human subjects. Short term (28 days) and long
term (9 months) repeated injections with a standard dose of 60 Units/kg and a high dose of 300 Units/kg were
administered to monkeys (n=4/sex/dose). Neither clinical drug-related adverse effects nor neutralizing antibodies were
detected in the animals. In a phase I clinical trial, six healthy volunteers were treated by intravenous infusions with
escalating single doses of prGCD. Doses of up to 60 Units/kg were administered at weekly intervals. prGCD infusions were
very well tolerated. Anti-prGCD antibodies were not detected. The pharmacokinetic profile of the prGCD revealed a
prolonged half-life compared to imiglucerase, the commercial enzyme that is manufactured in a costly mammalian cell
system. These studies demonstrate the safety and lack of immunogenicity of prGCD. Following these encouraging results, a
pivotal phase III clinical trial for prGCD was FDA approved and is currently ongoing.
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Introduction
Since its introduction in 1991, glucocerebrosidase enzyme
replacement therapy (ERT) has become the standard of care for
patients with symptomatic Gaucher disease due to its safety and
efficacy profile [1–4]. The success of ERT in Gaucher disease
ultimately led to the development of recombinant enzyme
treatments for other lysosomal storage diseases such as Fabry,
MPS-I, MPS-II, MPS-IV, Pompe and other lysosomal storage
disorders [5–11]. Currently, the enzymes used for treating
lysosomal storage disorders in general and in Gauchers disease
in particular are expressed in mammalian, Chinese Hamster ovary
cells (CHO)[1]. However, production of this enzyme in mamma-
lian cells is expensive, and the high cost of the approved
recombinant glucocerebrosidase for treating Gaucher’s disease, is
raising public concern [3,12,13].
In an attempt to offer an alternative source for the production of
the glucocerebrosidase enzyme, we have developed a biotechno-
logical expression platform which is based on the industrial scale
expression of human recombinant proteins in genetically engi-
neered plant cells [14]. The plant cell technology allows for a cost
efficient production system. In addition, the entire manufacturing
process is free from any animal-derived components, comple-
menting processing safety advantages as well. prGCD, is the most
clinically advanced recombinant plant system expressed protein to
undergo phase III clinical trials [15] and its chemical, functional
and genetic characterization, including the full amino-acid
sequence and its three dimensional crystal structure have recently
been described [14]. Following the successful completion of non-
clinical safety toxicology studies, which included a single dose
study in rodents [14] and a 28-day acute safety toxicology study in
primates (Cynomolgus monkeys) with daily dosing of prGCD,
regulatory approval for conducting a Phase I clinical trial was
allowed by the FDA. The clinical study in healthy human
volunteers was designed to evaluate the safety of three escalating
doses of prGCD and to determine the pharmacokinetics profile of
the drug. In addition, a nine-month chronic safety toxicology
study in primates (Cynomolgus monkeys) with dosing once every
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also performed. This study was a prerequisite for the initiation of
an advanced Phase III clinical trial, which will address the
continuing safety of chronic administration of prGCD.
Materials and Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Non clinical safety studies in Cynomolgus Monkeys
Two extensive safety toxicology studies were performed: an
acute 4-week daily intravenous infusion study and a chronic 39-
week intravenous infusion study in Cynomolgus Monkeys. In each
study, twenty four (24) animals (4/sex/dose) were intravenously
infused either daily (in the acute study) or once every 2 weeks (in
the chronic study) over 1 hr with multiples of 1 or 5 times the
clinical dose (60 units/kg) adjusted to animal body surface area.
The doses of 5.6 and 27.8 mg/kg/day represent 16and 56the
clinical dose on a mg/m
2 basis, respectively. The clinical dose of
60 units/kg, equivalent to approximately 1.8 mg/kg in humans,
corresponds to 66 mg/m
2 (using the conversion factor of 37 kg/
m
2 for humans), and corresponds to 5.6 mg/kg in cynomolgus
monkeys (using the conversion factor of 12 kg/m
2 for Cynomolgus
monkeys). Studies were performed according to Good Laboratory
Practice (GLP) at MPI Research (Mattawan, Michigan, USA).
This facility maintains an Animal Welfare Assurance statement
with National Institutes of Health, Office of Laboratory Animal
Welfare. All experiments were performed in accordance with the
guidelines of the Animal Care and Use Committee of the Hebrew
University. Animals were subjected to clinical observations and
assessed for body weight, hematology, coagulation, clinical
chemistry and urinalysis evaluations. Animals were sacrificed at
the end of treatment period and organ weights, macroscopic and
microscopic pathology were also determined. Antibodies were
measured on Day 1 and Day 28 in the acute study and on Day 1,
followed by 1, 3, 6 and 9 months in the chronic study. Plasma
concentrations and toxicokinetics were measured on Day 1 and
Day 28 in the acute study and on Day 1, Week 9 and Week 39 in
the chronic study.
Phase I clinical trial in healthy volunteers
The phase I study was designed as a single-center, non-
randomized, open label, safety and pharmacokinetic study of
escalating single doses of prGCD administered as intravenous
infusion (IV) to six healthy volunteers. This study was conducted
according to FDA and European GCP guidelines, and was
approved by the IRB of the Hadassah University Hospital and the
Israeli Ministry of Health and under an FDA investigational new
drug application (IND). The study was performed at the Phase I
Unit at the Goldyne Savad Institute of Gene Therapy at the
Hadassah Hebrew University Hospital. The study was approved
by the Helsinki committee of Hadassah-Hebrew University
Hospital Jerusalem, Israel, and all subjects gave written informed
consent. Inclusion and exclusion criteria are presented in Table 1.
Further information can be found at ClinicalTrials.gov website,
ClinicalTrials.gov Identifier: NCT00258778 (the study initiated
22
nd of Nov 2005 and was completed 20
th of March 2006).
Study Protocol
A vehicle control placebo followed by three single escalating
doses of prGCD were administered via intravenous (IV) infusions.
The vehicle was administered at the baseline visit, followed by an
initial prGCD dose of 15 units/kg administered on Day 8;
30 units/kg on Day 15, and 60 units/kg administered on Day 22.
The infusion rate was 1.5 mL/minute (135 mL over 90 minutes),
which was the same for all doses. Subjects were closely monitored
for 8 hours from the time of the initiation of the infusion and
returned after 24 hours from the time of initiation of infusion for
Table 1. Phase 1 study: Inclusion and Exclusion criteria.
Inclusion Criteria Exclusion criteria
Healthy male or female between 18 and 45 years of age Clinical evidence of any active significant disease that could potentially
compromise the ability of the investigator to evaluate or interpret the effects of
the study treatment on safety assessment and thus increase the risk to the subject
to unacceptable levels
Female subjects must agree to use a medically acceptable method of
contraception at all times during the study and must have a negative serum
pregnancy test at baseline and during the study period.
Are pregnant or nursing
Females of child-bearing potential must be non-pregnant and not lactating
and using adequate birth control such as oral contraceptives
Presence of any acute or chronic diseases
Negative laboratory tests for HIV, HBsAg or HCV Have a history of any allergies
Naive to any previous recombinant protein therapy Have been exposed to long-term steroid treatment
Provide written informed consent Had a minor operation in the last 6 months
Have the ability to understand the requirements of the study and to comply
with the study protocol and dosing regimen
Have ever been exposed to any previous recombinant protein therapy
Have received immuno-suppressive treatment
Have a positive HIV, HBsAg and HCV laboratory result
Use any medication other than vitamins or oral contraceptives (for female).
Have participated in another clinical trial during the previous 3 months
Have a history of alcohol or drug abuse
Are considered by the Investigator to be unsuitable candidate for this study.
doi:10.1371/journal.pone.0004792.t001
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was performed on day 29, at the end of the study. The issue of
safety was the primary outcome in this study; safety measurements
included adverse events, general infusion related toxicities,
physical examinations including changes in vital signs and body
weight, and laboratory tests. Pharmacokinetic parameters were the
secondary outcomes in this study. Blood samples were collected
prior to dosing (0) and at 5, 45, 80 and 90 minutes during the
infusion and 100, 115, 130, 150, 180, 210 minutes and 24 hours
from initiation of infusion, and the plasma was analyzed to provide
a pharmacokinetic profile (AUClast,T max,C max and Cmin).
The Pharmacokinetic analysis of the clinical samples was
performed by Midwest Bioresearch LLC, Skokie, IL, USA.
Statistical methods
Safety parameters at each follow-up assessment, as well as
changes from baseline, were examined and summarized for
descriptive purposes. Safety was also assessed through the recorded
adverse events. Adverse events were classified by body system
using the Medical Dictionary for Regulatory Activities (MedDRA),
and tabulated based on the incidence, severity, and causality to
study treatment.
Statistical analysis of the clinical trial data was performed by
TechnoStat Ltd., Kfar Saba, Israel.
Screening of anti-prGCD antibodies
Analysis of anti-prGCD antibodies was performed using a
validated immunoassay we have developed (Midwest BioResearch,
LLC, Skokie, Illinois). Controls and unknown samples were
incubated in a 96-well microtiter plate coated with prGCD
molecules and incubated with shaking at room temperature,
allowing any anti-prGCD antibodies present to bind to the
prGCD molecules. After incubation, the plate was washed to
remove any nonreactive serum components. Biotinylated prGCD
conjugate was added which enabled binding to anti-prGCD
antibodies already bound to the prGCD solid phase. Detection
was performed using a streptavidin-peroxidase conjugate. The
plate was washed to remove any unbound protein and reagents
followed by the addition of the substrate, tetramethylbenzidine
(TMB) solution. After a 10-minute incubation, 2 M sulfuric acid
was added and the absorbance was measured at 450 nm. The
intensity of the color produced was proportional to the
concentration of anti-prGCD antibodies in the sample. Anti-
body-positive samples were determined by comparing the optical
density (OD) with a predetermined cutoff OD. An OD equal to or
greater than the cutoff identifies a sample as antibody-positive.
Samples that were presumed positive underwent immunodepletion
testing by addition of prGCD. The addition of prGCD to samples
containing anti-prGCD was expected to block the anti-prGCD
antibodies from binding to the prGCD coat on the plate, thereby
decreasing the OD readings. Any sample demonstrating a
decrease of greater than 50%, after the addition of prGCD, was
considered positive for anti-prGCD antibodies.
Determination of neutralizing antibodies
Analysis of neutralizing antibodies was performed (Midwest
BioResearch, LLC, Skokie, Illinois) using a validated immunoas-
say we have developed. Controls and unknown samples were
incubated in a 96-well microtiter plate coated with prGCD
molecules and incubated with shaking at room temperature,
allowing any anti-prGCD antibodies present to bind to the
prGCD. After one hour of incubation at room temperature, the
plate was washed to remove any non-reactive serum components.
The substrate, p-nitrophenyl b-D-glucopyranoside, was mixed
with the activity assay buffer and added to the wells. After a one-
hour incubation at room temperature, 5 M sodium hydroxide was
added to stop the reaction and enhance the intensity of the color
developed. Control samples included neutralizing and non-
neutralizing controls. A solution of prGCD, substrate and enzyme
inhibitor conduritol B epoxide (CBE) which was added to the
uncoated wells was used to perform enzyme inhibition. The
control of pooled naive human serum was added to the coated
wells to track the activity of the enzyme coated to the surface of the
microtiter wells in the presence of normal human serum. A sample
is considered positive for neutralizing activity if the OD obtained is
less than or equal to the assay cutoff.
Determination of prGCD concentration in serum
Determination of prGCD plasma concentrations was performed
(Midwest BioResearch, LLC, Skokie, Illinois) using a validated
immunoassay we have developed. Controls and unknown samples
were incubated in a 96-well microtiter plate coated with chicken-
anti-plant recombinant glucocerebrosidase (prGCD) antibodies
and incubated with shaking at room temperature allowing any
prGCD present to bind to the anti-prGCD antibodies. After two
hours of incubation, the plate was washed to remove any non-
reactive plasma components. Rabbit anti-prGCD antibodies were
added and the plates were incubated 1.5 hours at room
temperature to allow the rabbit anti-prGCD to bind to the
prGCD. The plate was washed to remove any unbound protein
and reagents followed by the addition of an alkaline phosphatase
affinity-purified goat anti-rabbit IgG conjugate. After a 60-minute
incubation at room temperature, the plate was washed and
detection was performed with phosphatase substrate. The
absorbance was measured at 405 nm and color was allowed to
develop at room temperature for 30 to 45 minutes or until the
optical density (OD) was 1.0 or greater. The intensity of the color
produced was proportional to the concentration of prGCD in the
sample. The prGCD levels were quantified according to a
standard curve generated by measuring purified recombinant
prGCD in a 4% cynomolgus monkey plasma or human plasma
matrix utilizing a four-parameter curve fit equation.
Pharmacokinetic and Toxicokinetics Calculations
Plasma analysis data were analyzed by Noncompartmental
pharmacokinetic analyses (NCA) using WinNonlinH, version 5.0.1
software (Pharsight Inc., Mountain View, CA) and Microsoft
Office Excel 2003. Plasma prGCD concentration versus time data
for individual animals and human subjects were analyzed for
maximum concentration (Cmax), the time at which Cmax
occurred (Tmax), and for area under the plasma concentration
versus time curve from the start of infusion to 24 hours post-
infusion, using the linear trapezoid rule (AUCall). All AUC
calculations were based on the time interval from start of infusion
to the last measurable plasma concentration (AUClast). ,
Clearance (CL) and the volume of distribution at steady-state
(Vss) were determined.
Results
Safety and toxicology studies in primates
No treatment-related side effects on survival or any clinical signs
were observed during both the acute and chronic studies in
primates. There was no effect of prGCD on electrocardiogram
parameters, ophthalmological, hematological, coagulation, clinical
chemistry, or urinalysis values. Organ weights were not affected
and there were no investigational drug-related macroscopic or
histopathology findings. All changes were considered to be within
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observed-adverse-effect-level (NOAEL) of 27.8 mg/kg/day, the
highest dose tested, was identified.
In the acute study, repeated daily dosing of monkeys with
prGCD for 28 consecutive days did not result in production of any
anti-prGCD antibodies or neutralizing antibodies. In the chronic
study, samples from 5 of the 24 animals were found positive for
anti-prGCD antibodies, 3 out of 8 animals receiving 5.6 mg/kg/
day and in 2 out of 8 animals receiving 27.8 mg/kg/day. All
antibodies were determined to be negative for neutralizing
antibody activity.
All animals treated with prGCD had significant plasma
exposure to the investigational drug. The prGCD plasma exposure
profiles were similar at both dose levels. Plasma concentrations of
prGCD increased with increasing dose of prGCD.
Phase I Clinical Trial
Seventeen volunteers were assessed for eligibility. Six volunteers
were enrolled and allocated for the study. All six had completed all
study steps and their data was available for analysis. None had
dropped out during the study period. The volunteers, 3 males and
3 females, were all Caucasian aged 19–36.
Six healthy volunteers were administered with the vehicle at the
baseline visit, followed by an initial prGCD dose of 15 units/kg
administered on Day 8; 30 units/kg on Day 15, and 60 units/kg
on Day 22. Safety results indicated that prGCD was well tolerated
with only non-drug- related, minor side effects that were self
limited and resolved with no treatment. No serious adverse events
were attributable to prGCD administered intravenously once a
week at a dose of up to 60 units/kg. Laboratory tests for kidney
and liver function tests were all within normal range. One
volunteer had measurements of Bilirubin up to1.4 mg% (normal
values 0.3–1 mg%) during the follow-up period and a second
volunteer had measurements of Bilirubin up to 1.1 during the
follow-up period ; all the rest had normal Bilirubin levels within
normal limit all along the study.. Immunological laboratory tests
were all within normal limits. The Complete Blood Counts (CBC)
differentials revealed that one volunteer had at screening and at
follow-up a slight elevation in eosinophils, up to 7% (normal values
up to 5%; and his total WBC count was approximately 8,000/
cm3); and the second volunteer had a single measurement of 6%
of eosinophils (at a total WBC of 6,000/cm3). Complement
Component 3 (C3) measurements: 5 measurements were found to
be slightly lower than normal range. One subject had lower values
at screening and at Visit 1, which were normal afterwards. One
subject had three values lower than normal: at Visit 3, Visit 4 and
follow-up. None of these results were clinically significant. IgE
measurements were within normal range in five volunteers and
only one exhibited a slightly high value, which was similar to his
baseline and the vehicle control dosing period. Adverse events
were classified by body system using MedDRA, and tabulated
based on the incidence, severity, and causality to study treatment
(Table 2). Administration of prGCD did not result in the
formation of anti prGCD antibodies in any of the patients.
Overall, prGCD presents a high safety profile.
Pharmacokinetic profile
Comparison of prGCD concentration versus time for males
versus females at each dose level revealed no clear difference in
exposure between genders. Combining prGCD concentration for
males and females and plotting mean concentration versus time for
all three doses indicate dose-dependence in exposure to prGCD.
The pharmacokinetic profile, combined for 5 patients at 30 units/
kg and 60 units/kg is presented in Figure 1. All AUC calculations
were based on the time interval from start of infusion to the last
measurable plasma concentration (AUClast). Inspection of the
NCA results also confirmed no obvious difference between males
and females for Cmax and AUClast for these small group sizes. A
mean half-life (tK) of approximately 15 min (range: 8–32 min)
was determined and is based on all subjects in the 30 and
60 units/kg dose groups. At 30 and 60 units/kg, individual CL
values ranged from 0.8 to 3.4 mL/min/kg. Volume of distribution
(Vss) estimates ranged from 34 to 94 mL/kg at 30 and 60 units/
kg, which is consistent with the size of the human plasma
compartment.
Discussion
The primary objective of this Phase I clinical trial was to
determine the safety of recombinant plant cell expressed
glucocerebrosidase (prGCD) in healthy volunteers. The safety
results confirmed that there was no clinical or laboratory evidence
Table 2. Adverse events classified by body system using MedDRA, based on the incidence, severity, and causality to study
treatment
Relation between Event to drug
dose and severity Placebo 15 U/kg 30 U/kg 60 U/kg Event Severity Total # of events
Unrelated to drug (1) 0; 0 (0%) 0; 0 (0%) 0; 0 (0%) 2; 1 (17%) Moderate 2
Remotely related to drug (2) 1; 1 (17%) 4; 2 (33%) 1; 1 (17%) 2; 1 (17%) Mild 8
Possibly related to drug (3) 0; 0 (0%) 0; 0 (0%) 0; 0 (0%) 0; 0 (0%) __ 0
Probably related to drug (4) 0; 0 (0%) 0; 0 (0%) 0; 0 (0%) 0; 0 (0%) __ 0
Definitely related to drug (5) 0; 0 (0%) 0; 0 (0%) 0; 0 (0%) 0; 0 (0%) __ 0
(1) The event is clearly related to other factors, such as a subject’s clinical state, therapeutic interventions or concomitant medications.
(2) The event was most likely produced by other factors, such as a subject’s clinical state, therapeutic interventions or concomitant medications, and does not
follow a known response pattern to the study drug.
(3) The event has a reasonable temporal relationship to the study drug administration and follows a known response pattern to the study drug. However, a
potential alternate etiology may be responsible for the event. The effect of drug withdrawal is unclear. Re-challenge information is unclear or lacking.
(4) The event follows a reasonable temporal sequence from the time of drug administration, and follows a known response pattern to the study drug and
cannot be reasonably explained by non drug related factors. There is a reasonable response to withdrawal of the drug. Re-challenge information is not available or
advisable.
(5) The event follows a temporal sequence from the time of drug administration and follows a known response pattern to the study drug. Either
occurs immediately following the study drug administration, improves on stopping the drug, or reappears on repeat exposure.
doi:10.1371/journal.pone.0004792.t002
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investigational drug with any clinically significant adverse events.
prGCD administered IV once a week up to 60 mg/kg was shown
to be safe and non immunogenic. This data was strongly
supported by pre-clinical toxicological studies in animals including
primates, performed with prGCD. Based on these results, the US
Food and Drug Administration (FDA) allowed prGCD to proceed
to a Phase 3 pivotal clinical trial, which is currently ongoing. An
interesting finding in this study comes from the pharmacokinetic
results, wherein the half life of prGCD was prolonged relative to
that of CerezymeH (Genzyme Corporation, MA, USA), the
commercially available enzyme, reported as 3.6–10.4 min
[16](Genzyme website). While these data are based on a relatively
small number of human subjects, these findings have been
corroborated in the primate studies as well, and therefore probably
reflect a truly prolonged half life of the prGCD enzyme. At this
stage, it is impossible to predict whether this longer circulation
time in the blood would have any clinical advantage based on a
longer time of exposure to the mannose receptors on the
macrophages. Given the great similarity between the prGCD
and CerezymeH proteins, already reported at the level of their 3-D
structure [14], and based on the increased uptake of prGCD by
the tissue macrophages [14], it will be interesting to compare the
clinical outcome of prGCD treatment with the reported outcome
CerezymeH treatment.
Development of antibodies to the current commercially
available recombinant human glucocerebrosidase, expressed in
CHO cells, has been reported in approximately 15% of the treated
patients tested and antibody formation was reported following 3–
12 months of treatment [17,18,19]. Considering the relatively
small group size and the short duration of treatment (total of 4
weeks) in the human study, the lack of of antibodies to prGCD
formation is not surprising. This may also attributed to the high
homology with the endogenous protein [14]. The differences
between the reactions of the primates and human subjects has also
to do with the differences in the amount of prGCD given and the
frequency and duration of dosing (up to 27.8 mg/ml for 9 months
in primates and only up to 1.8 mg/ml in humans over a 4 week
period). The formation of antibodies to prGCD in Gaucher
patients will be further evaluated in the Phase 3 clinical study.
There is a public concern regarding the high cost of the
recombinant GCD enzyme approved for Gaucher’s disease
[3,12,13]. The plant cell system used for the expression of
prGCD has the potential to be highly advantageous due to the safe
and cost effective production of therapeutic recombinant glyco-
proteins that are not suitable for production in bacterial hosts, and
are currently being expressed in costly mammalian expression
systems. prGCD is produced in carrot cells, naturally possesses
terminal Mannose residues and therefore, prGCD production
does not require costly enzymatic deglycosylation as would be
required for the production of recombinant GCD in mammalian
cells [14]. Furthermore, it provides high batch-to-batch reproduc-
ibility of its glycan structures, which represents another important
advantage of plant cells. An additional advantage over mamma-
lian cells is the fact they do not involve mammalian-derived
components in the manufacturing process, making the purified
biopharmaceutical products less expensive and potentially safer
[3,20,21].
It remains to be determined in larger scale clinical studies, as
required in any new protein drug development process, whether
plant-derived biopharmaceutical glycoproteins are associated with
any excessive immunogenicity effects or excessive neutralizing
antibody formation, beyond the standard rate seen for recombi-
nant therapeutic proteins, which may limit their use. However, the
current regulatory viewpoint, based on data accumulated in a
number of clinical trials involving different plant-expressed
proteins, is quite promising in this regard [15,21]. The clinical
and preclinical data presented herein and reported previously
[14], demonstrated that there were no obvious treatment-related
adverse reactions or clinical findings, indicating the potential safety
of plant cell-expressed GCD.
Currently, several biotechnology companies have used plant
biotechnology to produce protein pharmaceuticals, such as
glucocerebrosidase to treat Gaucher disease in our case, lipase to
treat cystic fibrosis, alpha-interferon, lactoferrin, and others, which
are under evaluation in human studies [15]. The value and impact
of plant biotechnology on global health should not be dismissed.
Protein drugs, although quite costly, are widely used in the
developed world, but economic barriers make most of these new
biotechnology products inaccessible to the general public, but the
very wealthiest inhabitants of the developing world. It is likely that
another opportunity for plant-made biopharmaceuticals will take
place in the field of new versions of biopharmaceutical products or
‘‘biosimilar’’ versions of existing protein drugs. This is especially
true as patents on current drugs expire [22] or in those cases where
the patents do not protect the expression method of such proteins
in plants. The ongoing clinical trials evaluating these different
plant biotechnology produced protein-based pharmaceuticals will
enable to determine the merit of using these novel and highly
promising technologies.
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